Rentschler Biopharma Inc.
27 Maple Street
Milford
MA
01757
United States
Tel: 508-282-5800
Website: http://www.rentschler-biopharma.com/
About Rentschler Biopharma Inc.
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,000 employees. For more information, please visit www.rentschler-biopharma.com and for business development related information, please visit www.business.rentschler-biopharma.com
73 articles about Rentschler Biopharma Inc.
-
BioSpace Movers & Shakers, Sept. 24
9/24/2021
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
9/20/2021
Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Dr. Christian Schetter, Ph.D. as Chief Scientific Officer of Rentschler Biopharma SE, where he will be responsible for process technology and innovation, effective 15 September 2021.
-
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
-
August has been busy with a flurry of life sciences expansion announcements, particularly in the United States and Canada. Here’s a look at a few companies increasing their presence in the two countries.
-
Rentschler Biopharma breaks ground at new U.S. production site in greater Boston
8/12/2021
Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, announced that the company has broken ground at its new production site, adjacent to its existing site in Milford, MA in the greater Boston area.
-
Vetter and Rentschler Biopharma Further Strengthen their Strategic Alliance
4/28/2021
Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations, announced that their strategic collaboration has taken key steps forward.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Rentschler Biopharma appoints Dr. Martin Kessler as Chief Executive Officer of U.S. Subsidiary and as Senior Vice President Transformation
3/31/2021
Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Dr. Martin Kessler as Chief Executive Officer of Rentschler Biopharma Inc., the Company’s wholly owned U.S. subsidiary, and as Senior Vice President Transformation of Rentschler Biopharma SE, effective March 1, 2021.
-
Rentschler Biopharma and Leukocare extend service offering with joint U.S. site
3/22/2021
Leukocare joins Rentschler Biopharma in the U.S., facilitating integrated alliance capabilities and enhanced service for North American clients
-
Rentschler Biopharma to build new cell and gene therapy capabilities in the UK
2/11/2021
Rentschler Biopharma will establish their ATMP development and manufacturing capabilities at the Cell and Gene Therapy Catapult facility in Stevenage
-
Rentschler Biopharma establishes Center of Excellence for cell and gene therapy in the UK
2/11/2021
New enterprise, Rentschler ATMP Ltd., is part of continuous innovation at Rentschler Biopharma and supports ongoing strategic international expansion
-
Rentschler Biopharma and ATUM Announce Leap-In Transposase® Licensing Agreement for Development of Robust Manufacturing Processes for Complex Therapeutic Proteins
10/14/2020
License agreement provides Rentschler Biopharma full access to ATUM’s Leap-In Transposase® cell line development (CLD) tools
-
Joining Forces Against SARS-COV-2: Rentschler Biopharma Contributes to Manufacturing of COVID-19 mRNA Vaccine
10/8/2020
Rentschler Biopharma to provide cGMP manufacturing services for mRNA-based vaccine candidate, developed by BioNTech and Pfizer against SARS-CoV-2
-
Rentschler Biopharma and Vetter Team up With Joint Goal to Simplify Processes and Optimize Time-to-market
7/6/2020
Vetter and Rentschler Biopharma, two globally operating Contract Development and Manufacturing Organizations, announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain.
-
BioSpace Movers & Shakers, June 19
6/19/2020
Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Rentschler Biopharma SE appoints Alexander Dettmer as Chief Financial Officer
6/17/2020
Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Alexander Dettmer as Chief Financial Officer, effective July 1, 2020.
-
Rentschler Biopharma Extends Collaboration with Genmab to U.S. facility
5/27/2020
Innovative agreement provides flexible model to address Genmab’s development and manufacturing needs as programs advance in development Rentschler Biopharma’s U.S. site expansion progressing on track with plans to significantly increase square footage and number of employees
-
Rentschler Biopharma Licenses Horizon Discovery’s CHOSOURCE Platform to Complement Cell Line Development Offering for Difficult-To-Express Proteins
5/19/2020
CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield
-
As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.
-
Rentschler Biopharma Appoints New Executives to Join U.S. Team
11/18/2019
Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the hiring of two executives for its facility in Milford, MA, USA, in the greater Boston area.